(BNTX) BioNTech SE - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 22.646m USD | Total Return: -10.2% in 12m
mRNA Vaccines, Oncology Drugs, Infectious Disease Therapies
Total Rating 32
Safety 79
Buy Signal -1.05
Biotechnology
Industry Rotation: -18.1
Industry Rotation: -18.1
Market Cap:
22.6B
Avg Turnover: 82.6M
Avg Turnover: 82.6M
Risk 3d forecast
Volatility37.2%
VaR 5th Pctl5.57%
VaR vs Median-10.5%
Reward TTM
Sharpe Ratio-0.11
Rel. Str. IBD12.4
Rel. Str. Peer Group10.3
Character TTM
Beta1.015
Beta Downside1.338
Hurst Exponent0.545
Drawdowns 3y
Max DD37.35%
CAGR/Max DD-0.24
CAGR/Mean DD-0.50
EPS (Earnings per Share)
EPS CAGR: -38.82%
EPS Trend: -71.5%
EPS Trend: -71.5%
Last SUE: 0.07
Qual. Beats: 0
Qual. Beats: 0
Revenue
Rev. CAGR: -58.32%
Rev. Trend: -49.2%
Rev. Trend: -49.2%
Last SUE: -0.12
Qual. Beats: 0
Qual. Beats: 0
Warnings
High Debt/EBITDA (17.6) with thin interest coverage (-89.9)
Interest Coverage Ratio -89.9 is critical
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Description: BNTX BioNTech SE
BioNTech SE is a German biotechnology firm specializing in mRNA-based immunotherapies and precision medicine. While the company achieved global scale through its SARS-CoV-2 vaccine, its primary long-term focus is a diversified oncology pipeline targeting various solid tumors, including lung, breast, and colorectal cancers. The company utilizes a platform-based business model where proprietary mRNA technology is applied across infectious diseases and oncology to accelerate drug discovery.
The current clinical portfolio includes multiple candidates in Phase II and Phase III trials, such as Gotistobart and Pumitamig, alongside programs for tuberculosis and malaria. In the biotechnology sector, companies often face high research and development costs and significant regulatory hurdles before achieving commercialization for new drug classes. For a deeper look into these financial metrics and valuation trends, visit ValueRay.
Headquartered in Mainz, BioNTech operates through strategic partnerships and internal manufacturing capabilities to support its global clinical trials. The firm remains a central player in the shift toward individualized cancer treatments and next-generation vaccine technology.
- Declining COVID-19 vaccine demand significantly reduces core revenue and cash flow
- Oncology pipeline progression and Phase III clinical trial data drive valuation
- High research and development spending pressures short-term margins during transition
- Strategic expansion into antibody-drug conjugates diversifies revenue beyond mRNA technology
- Regulatory approval timelines for non-COVID therapies impact long-term growth prospects
Piotroski VR‑10 (Strict)
3.0
| Net Income: -1.26b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 11.87 > 1.0 |
| NWC/Revenue: 492.4% < 20% (prev 513.1%; Δ -20.67% < -1%) |
| CFO/TA 0.04 > 3% & CFO 858.0m > Net Income -1.26b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (252.9m) vs 12m ago 5.22% < -2% |
| Gross Margin: 73.17% > 18% (prev 0.79%; Δ 7.24k% > 0.5%) |
| Asset Turnover: 13.24% > 50% (prev 12.97%; Δ 0.27% > 0%) |
| Interest Coverage Ratio: -89.94 > 6 (EBITDA TTM -815.0m / Interest Expense TTM 14.2m) |
Altman Z''
10.00
| A: 0.65 (Total Current Assets 15.55b - Total Current Liabilities 1.77b) / Total Assets 21.10b |
| B: 0.83 (Retained Earnings 17.45b / Total Assets 21.10b) |
| C: -0.06 (EBIT TTM -1.28b / Avg Total Assets 21.14b) |
| D: 6.83 (Book Value of Equity 16.25b / Total Liabilities 2.38b) |
| Altman-Z'' Score: 13.75 = AAA |
Beneish M
-3.39
| DSRI: 0.59 (Receivables 612.8m/1.03b, Revenue 2.80b/2.75b) |
| GMI: 1.08 (GM 73.17% / 79.39%) |
| AQI: 0.99 (AQ_t 0.20 / AQ_t-1 0.20) |
| SGI: 1.02 (Revenue 2.80b / 2.75b) |
| TATA: -0.10 (NI -1.26b - CFO 858.0m) / TA 21.10b) |
| Beneish M-Score: -3.39 (Cap -4..+1) = AA |
What is the price of BNTX shares?
As of May 20, 2026, the stock is trading at USD 87.79 with a total of 733,475 shares traded.
Over the past week, the price has changed by -6.27%, over one month by -16.54%, over three months by -20.49% and over the past year by -10.24%.
Over the past week, the price has changed by -6.27%, over one month by -16.54%, over three months by -20.49% and over the past year by -10.24%.
Is BNTX a buy, sell or hold?
BioNTech SE has received a consensus analysts rating of 4.38.
Therefore, it is recommended to buy BNTX.
- StrongBuy: 13
- Buy: 3
- Hold: 5
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the BNTX price?
| Analysts Target Price | 125.5 | 43% |
BioNTech SE (BNTX) - Fundamental Data Overview
as of 17 May 2026
Market Cap EUR = 19.42b (22.65b USD * 0.8575 USD.EUR)P/E Forward = 7.0373
P/S = 8.0728
P/B = 1.0837
P/EG = 0.046
Revenue TTM = 2.80b EUR
EBIT TTM = -1.28b EUR
EBITDA TTM = -815.0m EUR
Long Term Debt = 246.1m EUR (from longTermDebt, last quarter)
Short Term Debt = 56.8m EUR (from shortTermDebt, last quarter)
Debt = 303.1m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -14.35b EUR (recalculated: Debt 303.1m - CCE 14.65b)
Enterprise Value = 5.07b EUR (19.42b + Debt 303.1m - CCE 14.65b)
Interest Coverage Ratio = -89.94 (Ebit TTM -1.28b / Interest Expense TTM 14.2m)
EV/FCF = 4.01x (Enterprise Value 5.07b / FCF TTM 1.26b)
FCF Yield = 24.91% (FCF TTM 1.26b / Enterprise Value 5.07b)
FCF Margin = 45.14% (FCF TTM 1.26b / Revenue TTM 2.80b)
Net Margin = -44.95% (Net Income TTM -1.26b / Revenue TTM 2.80b)
Gross Margin = 73.17% ((Revenue TTM 2.80b - Cost of Revenue TTM 750.7m) / Revenue TTM)
Gross Margin QoQ = -63.17% (prev 63.27%)
Tobins Q-Ratio = 0.24 (Enterprise Value 5.07b / Total Assets 21.10b)
Interest Expense / Debt = 1.34% (Interest Expense 4.07m / Debt 303.1m)
Taxrate = 21.0% (US default 21%)
NOPAT = -1.01b (EBIT -1.28b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.80 (Total Current Assets 15.55b / Total Current Liabilities 1.77b)
Debt / Equity = 0.02 (Debt 303.1m / totalStockholderEquity, last quarter 18.72b)
Debt / EBITDA = 17.60 (negative EBITDA) (Net Debt -14.35b / EBITDA -815.0m)
Debt / FCF = -11.36 (Net Debt -14.35b / FCF TTM 1.26b)
Total Stockholder Equity = 18.73b (last 4 quarters mean from totalStockholderEquity)
RoA = -5.95% (Net Income -1.26b / Total Assets 21.10b)
RoE = -6.72% (Net Income TTM -1.26b / Total Stockholder Equity 18.73b)
RoCE = -6.73% (EBIT -1.28b / Capital Employed (Equity 18.73b + L.T.Debt 246.1m))
RoIC = -5.31% (negative operating profit) (NOPAT -1.01b / Invested Capital 19.00b)
WACC = 9.42% (E(19.42b)/V(19.72b) * Re(9.55%) + D(303.1m)/V(19.72b) * Rd(1.34%) * (1-Tc(0.21)))
Discount Rate = 9.55% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 2.33 | Cagr: 1.81%
[DCF] Terminal Value 64.49% ; FCFF base≈1.26b ; Y1≈829.3m ; Y5≈379.3m
[DCF] Fair Price = 80.53 (EV 6.02b - Net Debt -14.35b = Equity 20.36b / Shares 252.9m; r=9.42% [WACC]; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -71.54 | EPS CAGR: -38.82% | SUE: 0.07 | # QB: 0
Revenue Correlation: -49.19 | Revenue CAGR: -58.32% | SUE: -0.12 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-2.40 | Chg30d=-76.89% | Revisions=-20% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.36 | Chg30d=-56.81% | Revisions=-20% | Analysts=2
EPS current Year (2026-12-31): EPS=-4.66 | Chg30d=-5.13% | Revisions=-25% | GrowthEPS=-871.2% | GrowthRev=-25.4%
EPS next Year (2027-12-31): EPS=-4.68 | Chg30d=-19.28% | Revisions=-25% | GrowthEPS=-0.3% | GrowthRev=+3.5%
[Analyst] Revisions Ratio: -25%